# Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a

> **NCT04773665** · PHASE1 · COMPLETED · sponsor: **VBI Vaccines Inc.** · enrollment: 114 (actual)

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** VBI-2902a
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** VBI-2905a

## Key facts

- **NCT ID:** NCT04773665
- **Lead sponsor:** VBI Vaccines Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-15
- **Primary completion:** 2022-11-14
- **Final completion:** 2022-11-14
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2024-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04773665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04773665, "Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04773665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*